Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01496573
First received: December 16, 2011
Last updated: December 17, 2011
Last verified: December 2011
  Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tumor tissue samples from younger patients with rhabdomyosarcoma.


Condition Intervention
Sarcoma
Genetic: gene expression analysis
Genetic: microarray analysis
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • CRKL expression at the protein level [ Designated as safety issue: No ]

Estimated Enrollment: 77
Study Start Date: December 2011
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue microarray (TMA).

OUTLINE: Archived tumor tissue samples are analyzed for CRKL expression.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma specimens from the Children Oncology Group (COG) tumor microarrays (TMAs)

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01496573

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Lee J. Helman, MD National Cancer Institute (NCI)
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01496573     History of Changes
Other Study ID Numbers: CDR0000719965, COG-ARST12B4
Study First Received: December 16, 2011
Last Updated: December 17, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
alveolar childhood rhabdomyosarcoma
embryonal childhood rhabdomyosarcoma
childhood rhabdomyosarcoma

Additional relevant MeSH terms:
Rhabdomyosarcoma
Myosarcoma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Sarcoma

ClinicalTrials.gov processed this record on September 30, 2014